67
Participants
Start Date
November 11, 2014
Primary Completion Date
January 31, 2019
Study Completion Date
January 14, 2019
Brentuximab Vedotin
Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1
Etoposide
Intravenose use, 40mg/m2/day, on days 1 to 4
Soludomerin
Intravenous use, 250mg/day, on days 1 to 4
Cisplatin
Intravenous use, 25mg/m2/day, on days 1 to 4
Ara C
Intravenous use, 2g/m2, day 5
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Universitario Ramón y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Hospital Universitario Central de Asturias, Oviedo
Hospital Universitario de Salamanca, Salamanca
Hospital Universitario de Canarias, Santa Cruz de Tenerife
Hospital Universitario Virgen del Rocío, Seville
Hospital Clínico de Valencia, Valencia
Hospital Son Espases, Palma
Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona
Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat
Hospital del Mar, Barcelona
Hospital Clinic i Provincial de Barcelona, Barcelona
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
OTHER